Last edition
News about "asedebart clinical development"
US FDA Grants Orphan Drug Designation to Lundbeck's Asedebart for Cushing's Syndrome
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Lundbeck’s investigational anti-ACTH antibody asedebart for endogenous Cushing’s syndrome; a proof-of-concept trial is ongoing.
Asedebart Clinical Development | 14/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members